<DOC>
	<DOCNO>NCT00986401</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability trospium chloride ( Sanctura XRâ„¢ ) metformin hydrochloride ( Glucophage ) co-administered .</brief_summary>
	<brief_title>Safety Tolerability Trospium Chloride Metformin Hydrochloride Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<criteria>Weight within +/30 % ideal body weight height frame size Nonsmoker ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 1 month prior screen visit ) . Willing abstain caffeinecontaining food beverage 24hours prior dosing , alcoholcontaining food beverage 48 hour prior dose , Seville oranges ( eg orange marmalade ) , grapefruit , grapefruit juice 7 day prior dose abstain throughout study . Willing abstain take medication ( exception hormonal contraceptive ) nonprescription medication include vitamin , food supplement , herbal preparation 7 day prior Day1 first treatment period throughout study . Uncontrolled systemic disease Known allergy sensitivity study medication ( ) ( Trospium , Metformin ) component Current enrollment investigational drug device study participation study within 30 day entry study . History myasthenia gravis closedangle glaucoma . Considering schedule undergo surgical procedure study . History alcohol substance abuse within 1 year prior Day1 first treatment period . History serious mental physical illness . Donated excess 500 mL blood 30 day prior screen visit . Required treatment medication , either prescription nonprescription ( include vitamin , antacid , acidreducers , food supplement , herbal preparation , exclude hormonal contraceptive ) , within 7 day prior Day1 first treatment period study . Had acute illness within 5 day prior Day1 treatment period . Had history hepatitis B C , positive test hepatitis B surface antigen , hepatitis C antibody , history human immunodeficiency virus ( HIV ) infection demonstration HIV antibody . Planned radiologic study require intravenous contrast administration iodinate contrast material study period Serum Creatinine great 1.4 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Adults</keyword>
</DOC>